NCT06574360View on ClinicalTrials.gov

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

March 31, 2029

Conditions
Schizophrenia
Interventions
DRUG

S1RA plus NMDAE

Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.

DRUG

S1RA plus Placebo Cap

Use of an S1R agonist plus placebo as a comparator

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
lead

China Medical University Hospital

OTHER